| Title |
Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients
|
|---|---|
| Published in |
Clinical Rheumatology, March 2007
|
| DOI | 10.1007/s10067-007-0594-1 |
| Pubmed ID | |
| Authors |
Kilian Verschueren, Els Van Essche, Patrick Verschueren, Veerle Taelman, Rene Westhovens |
| Abstract |
We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by etanercept. Both women, aged 46 and 53, had erosive, rheumatoid-factor-positive rheumatoid arthritis (RA) for 7 and 6 years, respectively. The eldest had received infliximab for over a year with good response, which was stopped because of a perfusion reaction. She developed a cough and dyspnea after 6 months of etanercept treatment. The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of etanercept. Imaging showed, in both cases, mediastinal adenopathies. Biopsies were compatible with sarcoidosis. Etanercept withdrawal led to a complete remission. Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving etanercept for a variety of diseases. In our cases, the temporal association with etanercept therapy and the complete remission after suspension of etanercept suggest a triggering role of this agent. Possible mechanisms of action and supporting evidence are discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 33% |
| Professor | 3 | 13% |
| Other | 3 | 13% |
| Student > Doctoral Student | 1 | 4% |
| Student > Master | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 5 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 63% |
| Nursing and Health Professions | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Energy | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 5 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2012.
All research outputs
#6,377,613
of 22,660,862 outputs
Outputs from Clinical Rheumatology
#954
of 2,977 outputs
Outputs of similar age
#24,300
of 76,024 outputs
Outputs of similar age from Clinical Rheumatology
#6
of 22 outputs
Altmetric has tracked 22,660,862 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 2,977 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,024 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.